03.11.2021 15:15:12
|
CVS Pharmacy To Offer Pfizer-BioNTech's COVID-19 Pediatric Vaccine Starting On Sunday
(RTTNews) - CVS Health (CVS) said that certain CVS Pharmacy will offer a two-dose primary series of the Pfizer-BioNTech COVID-19 pediatric vaccine to children ages five to 11 years of age starting on Sunday.
It follows authorization of the vaccine by the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices and Food and Drug Administration (FDA) Emergency Use Authorization.
The vaccine will be available at nearly 1,700 CVS Pharmacy locations in 46 states, Puerto Rico and Washington D.C., the company said.
In a separate press release, Rite Aid said it is prepared to begin administering doses of Pfizer-BioNTech's COVID-19 pediatric vaccine to children aged 5-11 as soon as the 10 microgram doses are distributed to Rite Aid, which is expected at the end of this week.
The first available appointments for age 5-11 doses will be on Saturday, November 6. Those appointments may be booked through our scheduling tool beginning Thursday, November 4.
The Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age is administered as a two-dose primary series, 3 weeks apart, but is a lower dose (10 micrograms) than that used for individuals 12 years of age and older (30 micrograms).
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu BioNTech (ADRs)mehr Nachrichten
26.11.24 |
BioNTech-Aktie tiefer: JPMorgan hat Ziel für BioNTech reduziert (dpa-AFX) | |
26.11.24 |
ANALYSE-FLASH: Goldman belässt Biontech auf 'Buy' - Ziel 137 Dollar (dpa-AFX) | |
20.11.24 |
BioNTech-Aktie auf Erholungskurs: Analysten loben BioNTech und sehen deutliches Aufwärtspotenzial (finanzen.at) | |
18.11.24 |
ANALYSE-FLASH: Goldman belässt Biontech auf 'Buy' - Ziel 137 Dollar (dpa-AFX) | |
15.11.24 |
Impfstoffwerte wie BioNTech unter Druck - Trump nominiert Skeptiker (dpa-AFX) | |
13.11.24 |
Biontech übernimmt chinesische Biotechnologie-Firma (dpa-AFX) | |
13.11.24 |
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus (Financial Times) | |
13.11.24 |
GNW-Adhoc: BioNTech kündigt Übernahme von Biotheus zur beschleunigten Umsetzung der Onkologie-Strategie an (dpa-AFX) |
Analysen zu BioNTech (ADRs)mehr Analysen
27.11.24 | BioNTech Buy | Deutsche Bank AG | |
26.11.24 | BioNTech Buy | Goldman Sachs Group Inc. | |
26.11.24 | BioNTech Buy | Jefferies & Company Inc. | |
19.11.24 | BioNTech Buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
18.11.24 | BioNTech Buy | Goldman Sachs Group Inc. |
Aktien in diesem Artikel
BioNTech (ADRs) | 113,80 | -0,26% | |
CVS Health Corp | 56,24 | -0,41% | |
Rite Aid Corp Registered Shs | 0,70 | -74,26% |